Important Safety Information
Compounded Tirzepatide Injection
Your licensed medical provider may prescribe compounded tirzepatide in a personalized dosage following a medical evaluation. Compounded medications are permitted under federal law but are not approved by the FDA and are not reviewed for safety, effectiveness, or manufacturing quality in the same way as FDA approved medications.
This summary does not contain all possible safety information or side effects and does not replace medical advice from your healthcare provider.
Indications and Use
Compounded tirzepatide is a prescription injectable medication that may assist adults with overweight or obesity in losing weight and maintaining weight loss when used alongside reduced calorie intake and increased physical activity.
It may be considered for individuals with:
- A body mass index of 27 kg/m² or greater with weight related medical conditions
- Obesity requiring medical weight management
Compounded tirzepatide acts as a dual GIP and GLP-1 receptor agonist to support metabolic and appetite regulation.
Compounded tirzepatide:
- Should not be used with other tirzepatide or GLP-1/GIP medications
- Has not been studied with other prescription or nonprescription weight loss products
- Has not been studied in individuals with prior pancreatitis
- Has not been established as safe or effective in patients under 18 years of age
FDA Status
Compounded tirzepatide is not FDA approved. Compounded medications are customized by pharmacies based on provider prescriptions and are not reviewed by the FDA for safety or effectiveness.
Boxed Warning
Risk of Thyroid Tumors
In animal studies, tirzepatide caused thyroid tumors including thyroid cancer. It is not known if this risk applies to humans.
Contact your provider immediately if you notice:
- Lump or swelling in the neck
- Hoarseness
- Difficulty swallowing
- Shortness of breath
Do not use compounded tirzepatide if you or a family member have had:
- Medullary thyroid carcinoma
- Multiple Endocrine Neoplasia syndrome type 2
Who Should Not Use Compounded Tirzepatide
Do not use if you:
- Have a personal or family history of medullary thyroid cancer
- Have MEN2 syndrome
- Have a known allergy to tirzepatide or formulation components
Administration Instructions
Compounded tirzepatide is injected under the skin once weekly in the:
- Abdomen
- Thigh
- Upper arm
Injection sites should be rotated weekly.
Your provider may gradually increase dosage over time based on response and tolerance.
Do not change your dose or stop treatment without consulting your provider.
Before Using Compounded Tirzepatide
Tell your provider about:
- All medications and supplements you take
- Diabetes medications including insulin or sulfonylureas
- History of pancreatitis
- Kidney disease
- Gallbladder disease
- Diabetic eye disease
- Depression or suicidal thoughts
- Pregnancy, plans to become pregnant, or breastfeeding
Tirzepatide should not be used during pregnancy. Stop treatment at least two months before attempting pregnancy.
Possible Side Effects
Common side effects may include:
- Nausea
- Vomiting
- Diarrhea
- Constipation
- Abdominal discomfort
- Fatigue
- Dizziness
- Injection site irritation
These effects often improve as treatment continues.
Contact your provider if symptoms persist or worsen.
Serious Side Effects Requiring Immediate Attention
Seek medical care immediately if you experience:
- Severe abdominal pain possibly radiating to the back
- Persistent vomiting
- Signs of gallbladder problems
- Vision changes
- Symptoms of low blood sugar
- Reduced urination or dehydration
- Allergic reactions such as swelling, rash, or difficulty breathing
- New or worsening mental health symptoms
Important Safety Reminders
- Never share needles, syringes, or medication vials
- Do not use compounded tirzepatide alongside other GLP-1 or weight loss medications
- Fully disclose medical history to your provider to reduce risk of complications
Typical Dosing Progression
Your provider may adjust dosing individually, but dosing commonly progresses gradually:
- Weeks 1 to 4: 2.5 mg weekly
- Weeks 5 to 8: 5 mg weekly
- Weeks 9 to 12: 7.5 mg weekly
- Weeks 13 to 16: 10 mg weekly
- Weeks 17 to 20: 12.5 mg weekly
- Weeks 21 and beyond: up to 15 mg weekly as tolerated
Maintenance doses may vary.
Always follow provider instructions.
Emergency Information
If you experience a medical emergency, call 911 or seek immediate medical care.
For overdose concerns, contact Poison Control at 1-800-222-1222.
Legal Disclosure
Compounded tirzepatide is not FDA approved and compounded products are not reviewed by the FDA for safety, quality, or effectiveness.